Sharon Natanzon (@NatanzonSharon) profile picture

Assistant Professor. Division of Cardiology, Heart Failure. University of Florida, Jacksonville.

Florida, USA
Joined March 2020
Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)Photo by Sharon Natanzon (@NatanzonSharon)
Had the opportunity to talk about heart failure on @FirstCoastNews Raising awareness is crucial to improving care and outcomes. #heartfailure #Cardiology #HealthAwareness firstcoastnews.com/video/ent…
2
1
1
17
1,340
Sharon Natanzon retweeted
Flail P2 with torrential MR, treated with M-TEER and reduced to trace-mild MR using two devices (MitraClip XTW and XT). A striking before-and-after comparison. #StructuralHeart #CardioTwitter @alizgheib @ufjaxcards
3
7
696
Sharon Natanzon retweeted
Multivalvular disease is challenging and remains an evidence gap. This CMR-powered study helps clarify the natural history of moderate AS with concomitant MR—a dual-valve phenotype with worse remodeling and outcomes than isolated severe AS. @JACCJournals #WhyCMR
1
7
2
13
1,437
🚨🫀 Cardiac CT is no longer just about coronary stenosis.
Photon-Counting CT is turning it into full cardiac phenotyping. And that changes everything. A new JACC editorial makes it clear: 👉 We are moving from coronary angiography to 👉 comprehensive myocardial + coronary characterization in one scan This is not an upgrade. This is a paradigm shift. What PCCT can now do: ✔ Coronary stenosis assessment ✔ Plaque characterization ✔ LV mass + function ✔ Extracellular volume (ECV) ✔ Late iodine enhancement (LIE) for fibrosis detection ✔ Myocardial tissue characterization 👉 All in a single examination And the numbers are impressive: Compared with CMR: 📊 LV mass index → r = 0.963 📊 Ejection fraction → r = 0.947 📊 ECV → r = 0.868 📊 LIE vs LGE → 99–100% segment concordance 📊 Diagnostic accuracy → AUC 0.994 📊 Sensitivity 99% | Specificity 100% Let that sink in. The real implication? We stop asking only: ❌ “Is there obstructive CAD?” And start asking: ✅ What is the plaque biology? ✅ Is there fibrosis? ✅ Is this hypertrophy, amyloid, HCM, or infiltration? ✅ What is the full cardiac phenotype? My take: This perfectly supports what many still underestimate: PCCT is not better coronary CTA. It is the beginning of a new cardiovascular imaging modality. From anatomy ➡️ to biology From stenosis ➡️ to disease From isolated findings ➡️ to integrated phenotyping ⚡ The future of cardiac imaging is not another test. 👉 It’s one scan that answers the real question: What is happening to this patient’s heart?
3
37
2
106
12,719
Sharon Natanzon retweeted
Welcome to another @MonteHeart Imaging and Clinical Lecture Friday, March 6, 2026. From 12:00 pm EST – 1:00 pm EST @salernomdphd Link: einsteinmed.zoom.us/j/941700…
2
12
1,088
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension: @CircAHA 🥸 Many patients have higher wedge + type 1 PulmHTN - this reports describes this group in detail. 😱 Take a look below: 👇👇👇👇
2
21
58
7,395
Sharon Natanzon retweeted
Acute eosinophilic myocarditis may present without peripheral eosinophilia in up to 57.4% of cases - making endomyocardial biopsy essential, as reliance on blood eosinophils risks missed diagnosis.ahajrnls.org/3Zii2BM
31
2
104
10,660
Sharon Natanzon retweeted
Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction Machine learning-based algorithm identifies HFpEF phenogroups with distinct clinical features and treatment responses. This study suggests that SGLT2i and ARNI have a role in improving the outcomes in patients with metabolic comorbidities and both systolic and diastolic impairment, while calcium channel blockers were most likely to benefit HFpEF patients with atrial fibrillation #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @hfcollaboratory @CircHF @TheLancet @mvaduganathan @hvanspall @BiykemB @AndrewJSauer @ankeetbhatt thelancet.com/journals/eclin…
1
6
38
2,163
Highly recommended conference
Just over a month left to register for our January 2026 three-day conference at Cedars-Sinai, “Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI,” with some of the most well-known speakers in the field. View the course agenda and register at cedars.cloud-cme.com/nuclear…
2
191
Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance CMR with ECV mapping can track changes in cardiac amyloid burden and treatment response in ATTR-CM, with changes in ECV being independently associated with outcomes. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @CMichaelGibson @DrMarthaGulati @hvanspall @Hragy @iamritu @AndrewJSauer @ankeetbhatt @biljana_parapid @AnastasiaSMihai @MasriAhmadMD academic.oup.com/eurheartj/a…
5
18
1,610
Stellar @SmidtHeart faculty-driven program, featuring the best of the best! Strongly recommended for anyone interested in cardiac imaging.
Just over a month left to register for our January 2026 three-day conference at Cedars-Sinai, “Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI,” with some of the most well-known speakers in the field. View the course agenda and register at cedars.cloud-cme.com/nuclear…
3
1
6
1,598
The Ultimate CPET Thread How to Decode Dyspnea Using Physiology (Braunwald + Clinical Insights) CPET is not just a stress test, It is a complete physiologic study of the heart, lungs, and muscles working together under stress A 🧵
4
52
4
156
21,710
Sharon Natanzon retweeted
SGLT2i & UTI: Continue or Stop? 🧩 Key Question: What happens when patients with T2DM on SGLT2 inhibitors develop a new-onset UTI? Should therapy be continued or discontinued thereafter? 🔍 Key Finding (EHJ, 2025 | doi:10.1093/eurheartj/ehaf788) In >61,000 T2DM patients on SGLT2i (2015–2022): 🔹 6.3% developed a new-onset UTI during follow-up. 🔹 Those with UTI had markedly higher risks of:   🫀 CV composite events (HR 3.18; 95% CI 2.88–3.51)   💧 Renal composite events (HR 2.51; 95% CI 2.32–2.72) After UTI, 32% stopped SGLT2i.  🚫 Discontinuation increased:   🫀 CV risk → HR 1.35 (1.20–1.53)   💧 Renal risk → HR 1.35 (1.21–1.51)  💊 No significant reduction in recurrent UTI risk (HR 0.96). 💡 Take-Home Message 🌊 New-onset UTI is a marker of vulnerability — signalling higher cardio-renal risk. ❌ Stopping SGLT2 inhibitors post-UTI worsens CV and renal outcomes, without lowering reinfection risk. ✅ Best approach:  – Treat UTI appropriately 🔬  – Resume or continue SGLT2 inhibitor once infection resolves  – Maintain long-term CV-renal protection 🌿 🩺 Clinical Insight “UTI is a complication; discontinuation is a setback.” Keep the molecule — protect the heart & kidney, not just the bladder. 💚 Source: 📘 European Heart Journal (2025): Wu M-Z et al., Urinary tract infection and continuation of sodium–glucose cotransporter-2 inhibitors in diabetic patients. 🔗 academic.oup.com/eurheartj/a…
2
79
3
213
18,922
Sharon Natanzon retweeted
Multimodality imaging in advanced #HeartFailure (part 2): #HFA_ESC Clinical Consensus Statement on #MCS & #HeartTransplantation 🫀 In #advancedHF care, #CVimaging is not just diagnostic, it is longitudinal surveillance across #LVAD and post-transplant care: 📍Candidate selection, ventricular+valve function, device positioning, unloading assessment, evaluation of #RV failure & device complications
📍Graft function, perfusion & rejection evaluation, CAV monitoring More🔗: doi.org/10.1002/ejhf.70018 @escardio @EJHFEiC @ESC_Journals @MarcoMetra @jozinetm @AlbertoAimo90 @MajaCikes @FinnGustafsson @kevin_damman @juliendreyfus1 #EchoFirst #yesCCT #whyCMR #ThinkPET
2
34
2
89
11,237
Sharon Natanzon retweeted
In symptomatic #nHCM, #mavacamten improved LV diastolic & LA function with modest LVH regression, but 1 in 5 demonstrated an #LVEF <50%, which reversed following therapy interruption. jacc.org/doi/10.1016/j.jacc.… #JACC #ESCCongress #WCCardio @DesaiMilindY
10
34
3,390
Sharon Natanzon retweeted
Treatment with #mavacamten for 48 weeks in #nHCM patients was associated with marked biomarker improvements compared with placebo. Long-term effects on remodeling, health status, and outcomes remain uncertain. jacc.org/doi/10.1016/j.jacc.… #JACC #ESCCongress #WCCardio @DesaiMilindY
1
15
1
48
5,925
Fantastic representation of the @UFMedicineJax heart failure team in Heart Failure Management 2025.
1
5
179
Sharon Natanzon retweeted
🆕💥📸 Cardiac CT 🍩for Prosthetic Heart Valve Assessment ☮️: Multi-societal Expert Consensus 👉🏼jacc.org/doi/10.1016/j.jacc.… #SCCT #ACC @RSNA @ACCinTouch @SCAI #NASCI #ESCR
2
24
53
4,198
Honored to be nominated for teacher of the year award. @ufjaxcards @UFMedicineJax
1
6
646
Sharon Natanzon retweeted
Currently in #JACCHF: FUTURE-HF, the first-in-human study of an implantable IVC sensor for remote HF monitoring, was found to be safe & feasible, with improvements in #NTproBNP, NYHA class, #QoL, & reduced #heartfailure events. More: jacc.org/doi/10.1016/j.jchf.… @kevin_damman @umcg
22
59
7,510